Improved Survival Among all Interferon-α-Treated Patients in HCV-002, a Veterans Affairs Hepatitis C Cohort of 2211 Patients, Despite Increased Cirrhosis Among Nonresponders

Digestive Diseases and Sciences

Volumn 61, Issue 6, 2016, Pages 1744-1756

  Cozen, Myrna L ^a   Ryan, James C ^a   Shen, Hui ^a   Cheung, Ramsey ^b   Kaplan, David E ^c   Pocha, Christine ^d   Brau, Norbert ^e   Aytaman, Ayse ^f   Schmidt, Warren N ^g   Pedrosa, Marcos ^e   Anand, Bhupinderjit S ^h   Chang, Kyong Mi ^c   Morgan, Timothy ⁱ   Monto, Alexander ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d VA MEDICAL CENTER   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f 800 Poly Pl (111 F)   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

^h MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

ⁱ VA LONG BEACH HEALTHCARE SYSTEM   (United States)

Author keywords

Cirrhosis; Hepatitis C; Hepatitis C therapy; Hepatocellular carcinoma; Survival

Indexed keywords

ALPHA INTERFERON; HEPATITIS B SURFACE ANTIGEN; RIBAVIRIN;

ADULT; ALCOHOL ABUSE; ANTIVIRAL THERAPY; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG ABUSE; ETHNICITY; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS C; HIGH RISK POPULATION; HUMAN; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL SERVICE; MIDDLE AGED; MIXED INFECTION; MORTALITY RATE; OVERALL SURVIVAL; PATIENT COMPLIANCE; PREVALENCE; PRIORITY JOURNAL; RACE DIFFERENCE; RETROSPECTIVE STUDY; TREATMENT FAILURE; TREATMENT OUTCOME; VETERAN; GOVERNMENT; PROPORTIONAL HAZARDS MODEL; UNITED STATES;

ADULT; COHORT STUDIES; FEMALE; HEPATITIS C; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RIBAVIRIN; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS;

EID: 84964076463     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-016-4122-5     Document Type: Article

References (43)

1. Butt AA. Hepatitis C virus infection: the new global epidemic. Expert Rev Anti Infect Ther. 2005;3:241–249.
2. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45:529–538.
3. McCombs J, Matsuda T, Tonnu-Mihara I, et al. The risk of long-term morbidity and mortality in patients with chronic hepatitis C: results from an analysis of data from a Department of Veterans Affairs Clinical Registry. JAMA Intern Med. 2014;174:204–212.
4. Yee HS, Chang MF, Pocha C, et al. Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. Am J Gastroenterol. 2012;107:669–689.
5. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370:1483–1493.
6. Ahn J, Flamm SL. Frontiers in the treatment of hepatitis C virus infection. Gastroenterol Hepatol (N y). 2014;10:90–100.
7. Hill A, Khoo S, Fortunak J, Simmons B, Ford N. Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries. Clin Infect Dis. 2014;58:928–936.
8. Tsui JI, Currie S, Shen H, et al. Treatment eligibility and outcomes in elderly patients with chronic hepatitis C: results from the VA HCV-001 Study. Dig Dis Sci. 2008;53:809–814.
9. Arase Y, Ikeda K, Suzuki F, et al. Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C. Intervirology. 2007;50:16–23.
10. Cainelli F. Hepatitis C virus infection in the elderly: epidemiology, natural history and management. Drugs Aging. 2008;25:9–18.
11. Butt AA, Wang X, Moore CG. Effect of hepatitis C virus and its treatment on survival. Hepatology. 2009;50:387–392.
12. Yoshida H, Arakawa Y, Sata M, et al. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology. 2002;123:483–491.
13. Kanwal F, Kramer JR, Ilyas J, Duan Z, El-Serag HB. HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV. Hepatology. 2014;60:98–105.
14. Morishima C, Shiffman ML, Dienstag JL, et al. Reduction in hepatic inflammation is associated with less fibrosis progression and fewer clinical outcomes in advanced hepatitis C. Am J Gastroenterol. 2012;107:1388–1398.
15. George SL, Bacon BR, Brunt EM, et al. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology. 2009;49:729–738.
16. Poynard T, Moussalli J, Munteanu M, et al. Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C. J Hepatol. 2013;59:675–683.
17. Cozen ML, Ryan JC, Shen H, et al. Nonresponse to interferon-alpha based treatment for chronic hepatitis C infection is associated with increased hazard of cirrhosis. PLOS One. 2013;8:e61568.
18. Bini EJ, Brau N, Currie S, et al. Prospective multicenter study of eligibility for antiviral therapy among 4084 U.S. veterans with chronic hepatitis C virus infection. Am J Gastroenterol. 2005;100:1772–1779.
19. Seal KH, Currie SL, Shen H, et al. Hepatitis C treatment candidacy and outcomes among 4318 US veterans with chronic hepatitis C virus infection: does a history of injection drug use matter? J Clin Gastroenterol. 2007;41:199–205.
20. Sofair AN, Barry V, Manos MM, et al. The epidemiology and clinical characteristics of patients with newly diagnosed alcohol-related liver disease: results from population-based surveillance. J Clin Gastroenterol. 2009;44:301–307.
21. Bundschus M, Dejori M, Stetter M, Tresp V, Kriegel HP. Extraction of semantic biomedical relations from text using conditional random fields. BMC Bioinform. 2008;9:207.
22. Donabedian A. The quality of care. How can it be assessed? JAMA. 1988;260:1743–1748.
23. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982.
24. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958–965.
25. Singal AG, Waljee AK, Shiffman M, Bacon BR, Schoenfeld PS. Meta-analysis: re-treatment of genotype I hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy. Aliment Pharmacol Ther. 2010;32:969–983.
26. Koretz RL, Arvaniti PM, Barrera V, et al. Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C. Cochrane Database Syst Rev. 2013; Art. No.: CD003617. doi:10.1002/14651858(1)
27. Sugimoto K, Stadanlick J, Ikeda F, et al. Influence of ethnicity in the outcome of hepatitis C virus infection and cellular immune response. Hepatology. 2003;37:590–599.
28. Kramer JR, Kanwal F, Richardson P, et al. Importance of patient, provider, and facility predictors of hepatitis C virus treatment in veterans: a national study. Am J Gastroenterol. 2011;106:483–491.
29. Dill MT, Makowska Z, Trincucci G, et al. Pegylated interferon-alpha regulates hepatic gene expression through transient JAK/STAT activation. J Clin Invest. 2014;124:1568–1581.
30. Oliviero B, Mele D, Degasperi E, et al. Natural killer cell dynamic profile is associated with treatment outcome in patients with chronic HCV infection. J Hepatol. 2013;59:38–44.
31. Nellore A, Fishman JA. NK cells, innate immunity and hepatitis C infection after liver transplantation. Clin Infect Dis. 2011;52:369–377.
32. Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology. 2002;122:1303–1313.
33. Shiffman ML, Hofmann CM, Thompson EB, et al. Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C. Hepatology. 1997;26:780–785.
34. Pradat P, Tillmann HL, Sauleda S, et al. Long-term follow-up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver-related complications. J Viral Hepat. 2007;14:556–563.
35. Bruno S, Battezzati PM, Bellati G, et al. Long-term beneficial effects in sustained responders to interferon-alfa therapy for chronic hepatitis C. J Hepatol. 2001;34:748–755.
36. Morgan RL, Baack B, Smith BD, et al. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med. 2013;158:329–337.
37. Zator ZA, Chung RT. After the cure: management of HCV after achievement of SVR. Curr HIV/AIDS Rep. 2013;10:428–435.
38. Di Bisceglie AM, Stoddard AM, Dienstag JL, et al. Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. Hepatology. 2011;53:1100–1108.
39. Morgan TR, Ghany MG, Kim HY, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology. 2010;52:833–844.
40. Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol. 2010;8:280–288.
41. Wiese M, Fischer J, Lobermann M, et al. Evaluation of liver disease progression in the German hepatitis C virus (1b)-contaminated anti-D cohort at 35 years after infection. Hepatology. 2014;59:49–57.
42. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med. 1999;340:1228–1233.
43. Rodger AJ, Roberts S, Lanigan A, et al. Assessment of long-term outcomes of community-acquired hepatitis C infection in a cohort with sera stored from 1971 to 1975. Hepatology. 2000;32:582–587.